Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis

Erin Dodd, Kristen P Hook

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.

Original languageEnglish (US)
Pages (from-to)e184-e185
JournalPediatric Dermatology
Volume33
Issue number3
DOIs
StatePublished - May 1 2016

Fingerprint

imiquimod
Langerhans Cell Histiocytosis
Skin
Therapeutics
Tacrolimus
Exanthema
Adrenal Cortex Hormones
Steroids
Recurrence

Cite this

Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis. / Dodd, Erin; Hook, Kristen P.

In: Pediatric Dermatology, Vol. 33, No. 3, 01.05.2016, p. e184-e185.

Research output: Contribution to journalArticle

@article{a1ef6f1ccc6a46ce937143f4f5287aa9,
title = "Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis",
abstract = "Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5{\%} topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.",
author = "Erin Dodd and Hook, {Kristen P}",
year = "2016",
month = "5",
day = "1",
doi = "10.1111/pde.12829",
language = "English (US)",
volume = "33",
pages = "e184--e185",
journal = "Pediatric Dermatology",
issn = "0736-8046",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Topical Imiquimod for the Treatment of Childhood Cutaneous Langerhans Cell Histiocytosis

AU - Dodd, Erin

AU - Hook, Kristen P

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.

AB - Although topical steroids are considered first-line treatment for cutaneous Langerhans cell histiocytosis (LCH), the appropriate therapy for refractory cases remains controversial. We report a 16-month-old girl with isolated cutaneous LCH refractory to treatment with topical corticosteroids and topical tacrolimus. Treatment was initiated with 5% topical imiquimod cream and the rash completely resolved after 5 months of therapy. There was no disease recurrence after more than 2 years of follow-up. We present this case to highlight imiquimod as a novel therapeutic agent for the management of isolated cutaneous LCH in children.

UR - http://www.scopus.com/inward/record.url?scp=84963699536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963699536&partnerID=8YFLogxK

U2 - 10.1111/pde.12829

DO - 10.1111/pde.12829

M3 - Article

C2 - 27040152

AN - SCOPUS:84963699536

VL - 33

SP - e184-e185

JO - Pediatric Dermatology

JF - Pediatric Dermatology

SN - 0736-8046

IS - 3

ER -